[6-K] GSK plc American Current Report (Foreign Issuer)
Filing Impact
Filing Sentiment
Form Type
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK
plc (the
'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Sally Jackson
|
|||
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
1
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dylan Jackson
|
|||
|
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
1
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Victoria Whyte
|
|||
|
b)
|
Position/status
|
Company
Secretary
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
139
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Iain Whyte
|
|||
|
b)
|
Position/status
|
PCA of Ms V Whyte (Company Secretary)
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
1,290
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Emma Walmsley
|
|||
|
b)
|
Position/status
|
Chief
Executive Officer
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
118.489
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Diana Conrad
|
|||
|
b)
|
Position/status
|
Chief People Officer
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
1,380.565
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
James Ford
|
|||
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
2,315.664
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Sally Jackson
|
|||
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
862.794
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dylan Jackson
|
|||
|
b)
|
Position/status
|
PCA of Sally Jackson (SVP,
Global Communications and CEO Office)
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
156.971
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
David Redfern
|
|||
|
b)
|
Position/status
|
President Corporate Development
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
7,028.653
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Regis Simard
|
|||
|
b)
|
Position/status
|
President, Global Supply Chain
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
2,929.122
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Philip Thomson
|
|||
|
b)
|
Position/status
|
President, Global Affairs
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
2,401.114
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Kate Thomson
|
|||
|
b)
|
Position/status
|
PCA of Philip Thomson (President, Global Affairs)
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
122.458
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Deborah Waterhouse
|
|||
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
1,432.489
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Tony Wood
|
|||
|
b)
|
Position/status
|
Chief Scientific Officer
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
1,422.165
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Victoria Whyte
|
|||
|
b)
|
Position/status
|
Company
Secretary
|
|||
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 10 July 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.4903
|
1.491
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2025-07-11
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
15, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
Source:
GSK PLC
NYSE:GSK
GSK Rankings
GSK Latest News
GSK Latest SEC Filings
GSK Stock Data
74.12B
2.04B
0.06%
18.29%
0.67%
Drug Manufacturers - General
Healthcare
United Kingdom
London